 Connection
Joaquin Espinosa to Antineoplastic Agents
This is a "connection" page, showing publications Joaquin Espinosa has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.956 |
|
|
|
-
Andrysik Z, Espinosa JM. Harnessing p53 for targeted cancer therapy: new advances and future directions. Transcription. 2025 Feb; 16(1):3-46.
Score: 0.433
-
Szwarc MM, Guarnieri AL, Joshi M, Duc HN, Laird MC, Pandey A, Khanal S, Dohm E, Bui AK, Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. FAM193A is a positive regulator of p53 activity. Cell Rep. 2023 03 28; 42(3):112230.
Score: 0.377
-
Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, Wilky BA, Elias A, Espinosa JM, Sullivan KD. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer Res. 2023 08 01; 83(15):2543-2556.
Score: 0.097
-
Kalet BT, McBryde MB, Espinosa JM, Koch TH. Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism. J Med Chem. 2007 Sep 06; 50(18):4493-500.
Score: 0.032
-
Fitzwalter BE, Towers CG, Sullivan KD, Andrysik Z, Hoh M, Ludwig M, O'Prey J, Ryan KM, Espinosa JM, Morgan MJ, Thorburn A. Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell. 2018 03 12; 44(5):555-565.e3.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|